Noninvasive disease monitoring and risk stratification by circulating tumor DNA (ctDNA)
profiling has become a potential novel strategy for patient management in B-cell lymphoma …

Non-Hodgkin lymphomas represents a heterogeneous group of lymphoproliferative
disorders characterized by different clinical courses, varying from indolent to highly …

High-risk large B-cell lymphoma (LBCL) has poor outcomes with standard first-line
chemoimmunotherapy. In the phase 2, multicenter, single-arm ZUMA-12 study …

Purpose Outcomes for patients with diffuse large B-cell lymphoma remain heterogeneous,
with existing methods failing to consistently predict treatment failure. We examined the …

We assessed the predictive value of new radiomic features characterizing lesion
dissemination in baseline 18F-FDG PET and tested whether combining them with baseline …

Abstract FDG‐PET/CT is the current state‐of‐the‐art imaging in lymphoma and plays a
central role in treatment decisions. At diagnosis, accurate staging is crucial for appropriate …

PET/CT molecular imaging has been imposed in clinical oncological practice over the past
20 years, driven by its two well-grounded foundations: quantification and radiolabeled …

Rituximab plus polychemotherapy is the standard of care in diffuse large B-cell lymphoma
(DLBCL). GAINED, a randomized phase 3 trial, compared obinutuzumab to rituximab …

As part of a randomized, prospective clinical trial in large cell lymphoma, we conducted
serial fluorodeoxyglucose positron emission tomography (FDG-PET) at baseline, after 2 …

This Review focuses on the use of 18 F-fluorodeoxyglucose (18 F-FDG) PET in the
assessment of diffuse large B-cell lymphoma, follicular lymphoma, and peripheral T-cell …